India Pharma Outlook Team | Monday, 01 September 2025
India is scheduled to overhaul the regulations under the Biological Diversity Act, 2002 with the intention of boosting the ayurvedic medicine, pharmaceutical, and wellness sectors, and at the same time, ensuring sustainable biodiversity conservation.
The reforms ease the approval processes, waive access and benefit-sharing fees for start-ups and small businesses with turnover below ?5 crores; and reduce the time needed for research and product clearance by a large margin. In the past, companies that required access to biological resources and traditional knowledge had to go through lengthy and complicated procedure.
The National Biodiversity Authority (NBA) is leading this amazing venture under the Ministry of Environment, Forest and Climate Change. The regulators are in a position to choose the right balance between progression and sustainability.
Also Read: Lilly's Oral GLP-1 Orforglipron Shows Success in Phase 3 Trial
Industry stakeholders, such as ADMA, CII, and FICCI, among others, have warmly embraced the development. Sargam Dhawan, Director of Planet Herbs Lifesciences, while appreciating the reforms, said that the amendments "strike a healthy balance between sustainability and ease of doing business," also encouraging the strong protection of traditional knowledge.
Experts believe that the alterations will speed up India’s bio-economy, which will put the country in a leading position in herbal sciences all over the world, and that will also be a guarantee that India’s abundant biodiversity keeps flourishing way into the future.
